ABIVAX Société Anonyme (ETR:2X1)

Market Cap	8.27B +2,196.5%
Revenue (ttm)	5.31M -42.9%
Net Income	-293.52M
EPS	-4.46
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	789
Average Volume	2,217
Open	104.80
Previous Close	98.10
Day's Range	103.20 - 106.60
52-Week Range	68.10 - 132.20
Beta	n/a
RSI	57.32
Earnings Date	Mar 23, 2026

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 67
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 2X1

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.